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Seven novel lead compounds, acting as NNRTIs of HIV-1, are extracted from a database of, in silico de novo designed, 
500 compounds. Functional group based computational molecular modelling techniques are used for such design of 
Acylthiocarbamate derivatives. Effect of structural characteristics on the antiviral activity of these derivatives has also been 
studied. Statistical regression techniques namely, Non-linear (Back Propagation Neural Network, Support Vector Machine) 
and linear (Multiple Linear) chemometric regression methods are used in developing the relationships of Kier-Hall 
Electrotopological State Indices (ERingA, EO8, EN9, EO14, ES16, EN17, EO19, ER, and ER1) with the HIV-1 antiviral activity.  
The relative potentials of these methods are also assessed and the results suggest that BPNN (r2 = 0.845, MSE = 0.142,  
q2 = 0.818) describes the relationship between the descriptors and antiviral activity in a relatively better manner than  
SVM-ε-radial (r2 = 0.844, MSE = 0.144, q2 = 0.807) and MLR (r2 = 0.836, MSE = 0.150, q2 = 0.805).  
Keywords: Back Propagation Neural Networks (BPNN), De Novo Design, Molecular Modeling, Multiple Linear 
Regression (MLR), NNRTIs, Support Vector Machine (SVM) 
In the voyage of clinical management of AIDS, 
NNRTIs play key role which help eradicate the 
infection caused by HIV-11-5. As NNRTIs are 
impeded the conversion of single stranded viral RNA 
into double stranded pro-viral DNA in the HIV-1 life 
cycle at very initial stage. Despite the efficiency  
of NNRTIs, the genetic mutation in virus,  
toxicity, difficult treatment regimens, inadequate 
pharmacology (bioavailability and tissue distribution) 
and side effects of present medications, still confronts 
the journey of AIDS treatment6-8. To conquer these 
challenges there is an urgent need to develop 
innovative potent drug(s) with broad spectrum of 
pharmacokinetic profile that are able to provide 
higher genetic barrier to resistance and reduced  
safety problems. 
From past few decades computational modelling 
techniques have been established as valuable tools in 
assisting new drug discovery process9-11. These are 
relatively less expensive techniques, which speed up 
the drug discovery process and help in producing 
novel and potent molecules with desired biological 
activity. 2D/3D-QSAR/QSPR, molecular docking, 
virtual screening etc. are some of the common 
computational modelling techniques used in drug 
development and discovery12-14.  
Materials and Methods 
 
Molecular Dataset and Computational methods 
In the present work de novo design of novel NNRIs 
of HIV-1 is carried out using functional group based 
computational molecular modelling techniques using 
3D-Kier-Hall Electrotopological state (E-state) indices. 
Also, work is performed with an additional goal to get 
insight into the effect of structural characteristics on the 
antiviral activity of a dataset of 78 Acylthiocarbamate 
(ATC) derivatives, a diverse class of compounds acting 
as a NNRTIs of HIV-115-19. The structures are drawn and 
optimized using ChemDraw Ultra version 7.0.0 and 
Chem3D Ultra version 7.0.0 respectively20. Kier-Hall E-
state indices for various functional groups are calculated 
using Toxicity Estimation Software Tool21. Molegro 
Data Modeller tool of the Molegro Virtual Docker 
software 2.6.0 is used for regression analyses and 
deriving correlation of E-state indices with the antiviral 
activity (pEC50, in µM terms)
 22. The flow of work is 
presented as Scheme 1. 
 
Kier-Hall electrotopological state (E-State) indices 
The Kier-Hall Electrotopological state indices  
(E-State) are atom level descriptors encoding both the 
electronic character and topological environment of each 
skeletal atom. They are formulated using intrinsic value Ii 




and a perturbation term ΔIi, arising from the 
electronic interactions within the molecular 
topological environment of each atom in molecule23-
31. Using E-State descriptors one can demonstrate 
structural specificity of a molecule at an atomic or 
fragmental level.  
 
Molecular modeling and chemometric analyses  
A functional group based 3D-quantitative structure 
activity relationship (3D-QSAR) is developed using the 
Kier-Hall Electrotopological indices. E-state indices for 
various functional groups are calculated. Non-linear 
(BPNN and SVM) and linear (LR and MLR) 
regression methods are used in deriving the 
relationships and understanding the correlation 
potential of the methods. The potential of the Kier-
Hall E-state indices and structural attributes 
responsible for affecting biological activity of the 
molecules are studied. A variety of chemometric 
methods are  used for handling multivariate data and 
are responsible for reliable QSAR interpretations32-34. 
A brief account of chemometric methods used in the 
study is presented herewith. 
 
 




Back propagation neural network (BPNN) 
Neural networks resemble human brain neuron 
network and can handle complex and non-linear data 
and thus extract the hidden relationships between  
the dependent and independent variables35. Rumelhart 
et al36., developed the Back-Propagation Neural 
Network (BPNN) as a solution to the problem of 
training multi-layer perceptrons37-40.  
 
Support vector machine (SVM) 
SVM is based on the structural risk minimization 
(SRM) principle which is least sensitive to data over 
fitting41. SVM techniques are introduced by Boser, 
Guyon and Vapnik42. This method can be applied to 
linear as well as nonlinear classification and are trained 
faster43. SVM has been successful in correlating 
various quantitative structure activity/property 
relationships in the areas of computer-aided drug 
design methods44-48. It is a supervised learning method 
and support vectors are used with suitable kernel 
functions. For the present study ν- and ε-support vector 
regressions based on LIBSVM are considered and in 
each case linear, polynomial, sigmoid, and radial basis 
functions are used. 
 
Multiple linear regressions (MLR)  
Multiple linear regression (MLR) is a method where 
the values of the regression coefficients (bn’s) are 
evaluated using least squares curve fitting method49,50. 
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Where, ‘y’ is the dependent variable, ‘x1, x2 .... xn’ are 
the independent variables, ‘b1, b2 .... bn’ are the 
regression coefficients and ‘c’ is the intercept on Y 
axis and is constant.  
This is the most widely used method owing to its 
fast and easy interpretability. However, for complex 
systems, such as a biological system, the linear 
combination of descriptor information can often lead 
to a model with limited accuracy, simply due to the 
assumption of linearity in the data. 
 
Results and Discussion 
Supplementary Data, Table S1 records the structure 
of 78 ATC derivatives along with the position of 
substituents, antiviral activity (pEC50, in µM terms) 
and the E-state indices (ERingA, EO8, EN9, EO14, ES16, 
EN17, EO19, ER, and ER1). The dataset is split into a 
training set (n=53) and test set (n=19). BPNN, SVM 
and MLR techniques are used for generating 
regression models to establish correlation between the 
E-state indices (descriptors) and antiviral activity 
(pEC50), thereby establish the effect of substitution on 
the activity. The results thus obtained are then used 
for generating a virtual dataset (VDS) of ATC 
analogues. Using the best model thus generated, the 
pEC50 of VDS is estimated and compounds exhibiting 
high anti-viral activity are extracted. 
 
Correlation analyses 
To assess the effect of substituents, E-state 
descriptors are correlated with the antiviral activity, 
generating various nonlinear and linear-regression 
models. Uni-variate, bi-variate and multi-variate models 
are generated for assessing the referred potential. 
 
Univariate correlation  
A univariate structure activity relationship is 
developed between the E-state values and antiviral 
activity for the training set. The impact of individual 
substituent on the antiviral activity is determined 
using linear equation expressed as pEC50= bX+c, 
where X is the independent variable (descriptor), ‘b’ 
is the coefficient and ‘c’ is the constant. The results  
of correlations and impact of descriptors (substituent) 
are presented in Table 1. From this table it is observed 
that the relationship of descriptors with the activity 
shows following order of correlation (assessed  
in terms of correlation coefficient, r2): ER1(0.135) > 
ERingA (0.075) > EN9(0.069) > EO14(0.055) > 
ES16(0.054) > EN17(0.044)> ER (0.008) > EO19(0.001) = 
EO8(0.00). While the effect (impact) of each descriptor 
on the antiviral activity is expressed in terms  
of the coefficient of respective descriptors and is 
referred as Impact Coefficient (IC). It follows  
the following order: EN9(−6.114) > EO14(−3.224) > 
ES16(−3.184) > EN17(−1.415) > ERingA (−0.968) > 
EO8(−0.319) > EO19(0.146) > ER1(0.040) > ER 
(−0.023). 
Table 1 — The univariate correlation (r2) and impact (IC) 
coefficients of e-state descriptors with pEC50 (µM) and linear 
equation for ATC analogues (Training set) 




ERingA 0.075 -0.9689 pEC50 = -0.9689 * ERingA + 14.54
EO8 0.000 -0.3197 pEC50 = -0.3197 * EO8 + 11.28 
EN9 0.069 -6.1149 pEC50 = -6.1149 * EN9 + 13.86 
EO14 0.055 -3.2248 pEC50 = -3.2248 * EO14 + 25.41 
ES16 0.054 -3.1841 pEC50 = -3.1841 * ES16 + 24.40 
EN17 0.044 -1.4155 pEC50 = -1.4155 * EN17 + 8.90 
EO19 0.001 0.1465 pEC50 = 0.1465 * EO19 + 5.33 
ER 0.008 -0.0232 pEC50 = -0.0232 * ER + 7.58 
ER1 0.135 0.0409 pEC50 = 0.0409 * ER1 + 6.58 




It is observed that there is no direct association 
between impact coefficient(IC) and linear correlation 
coefficient (r2). From the values of impact coefficient 
it is observed that EN9 has highest, though in a highly 
retarding manner, while EO19 has a little enhancing 
and other substitutents impart moderate to low, 
impacts on anti viral activity. To assess 
interrelationship between individual descriptors and 
antiviral activity numerous nonlinear analyses are 
performed. The relative potential of each descriptor 
on the antiviral activity (in terms of impact coefficient 
of each descriptor) using univariate regression 
technique is presented in Fig. 1. 
 
Back propagation neural network (BPNN) analyses  
To assess the interdependence and relative level 
(relevance score) of effect of the E-state descriptors 
on antiviral activity of ATC derivatives, Back 
Propagation Neural Network (BPNN) analyses are 
performed. The following parameters are set to train 
the network: maximum training epoch = 10000, 
learning rate = 0.30, output layer learning rate = 0.30, 
momentum = 0.20, data range normalization =  
0.1-0.9, number of neurons = 1, and initial weight = 
±0.50. Leave-one-out (LOO) and N-cross validation 
(N-CV) methods are used in validating the results. 
The results obtained suggest that LOO method 
performed better with the higher r2 and lower MSE 
than other validation methods for BPNN.  
The order of relevance score of correlation for E-
state descriptors with antiviral activity is as follows: 
ES16(100) > EO14(81) > ER1(69) > EN9(67) > EO8(61) > 
ERingA (58) > EN17(54) > ER (39) > EO19(13). 
Assessment of above order indicates that ES16 has 
highest impact while the EO19 has the lowest impact 
on antiviral activity. The other E-state descriptors 
namely EO14, ER1, EN9, EO8, ERingA, EN17, ER have 
moderate to low impact on antiviral activity. The 
relevance score for each descriptor, as estimated using 
BPNN technique, is presented in the Fig. 2. 
 
Multiple linear regression (MLR) analyses 
MLR is performed to evaluate relative potential of 
E-state descriptors on the antiviral activity of ATC 
derivatives in multivariate linear terms. The best 
model for relating the descriptor values with antiviral 
activity (pEC50) derived using MLR method is 
presented in Eqn (2): 
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(n=53 r2=0.8368 r2adj=0.8027 spearman 
rho=0.7652 MSE=0.1501). 
Eqn (2) is exhibiting the coefficients for all the 
functional groups (presented in the form of E-State 
descriptors). This suggests that these can be divided in 
to three categories: (a) activity enhancing, (b) activity 
retarding and (c) moderately affecting. 
The high positive coefficients of "ES16", "EO8", 
"EN17" and " ERingA " suggest that these functional 
groups impart an activity enhancing effect on the 
antiviral activity while high negative coefficients for 
"EO14" and "EN9" indicate that presence of bridging 
oxygen atom at '14' position and nitrogen atom in the 
five member ring will adversely affect the antiviral 
activity and thus will retard the activity. Though, the 
coefficients of EO19, ER and ER1 are positive but are 
 
 
Fig. 1 — Bar chart presenting the impact of each E-state index on 
anti-HIV-1 activity of ATC derivatives as obtained from 
univariate linear analysis. 
 
Fig. 2 — Bar chart presenting the relevance score of E-state 
indices of ATC derivatives as obtained from BPNN analysis. 




very low  and thus their activity enhancing  
impact on the antiviral activity will be to a lower 
extent and thus can be classified as moderately 
affecting groups. 
 
Support vector machine regression (SVM) analyses 
ε-support vector regression and -support vector 
regression with variable kernels [linear (SVM-LK), 
polynomial (SVM-PK), sigmoid (SVM-SK), and 
radial basis function (SVM-RBFK)] are considered 
and eight models are generated using a random seed 
3485805689. Optimal parameter settings are fine-
tuned and accordingly results are obtained. The 
following  parameters, Cost: 100000, Gamma= 
0.0003, Epsilon (ε): 0.001/ Nu (): 0.5, Termination 
criterion tolerance: 0.01 are chosen for performing the 
regression analyses. It is observed that the radial basis 
function kernel performs best, followed by 
polynomial and linear kernels in ε and  techniques 
both. In all the cases the correlation coefficients are 
comparable. In either case the sigmoid kernels 
perform poorly. The results obtained using SVM 
method can be attributed to non-linearity among the 
various parameters and also signifies the robustness of 
the derived models. 
 
Comparative Analyses 
On comparison of the results obtained from the three 
methods it is observed that BPNN regression method 
show highest correlation potential followed by SVM 
regression methods (ε-RBFK and -RBFK) while the 
MLR method shows lowest. Table 2 presents  
the comparative analyses of all the three methods. 
 
Cross validation with test set  
To validate the QSAR models thus obtained from 
BPNN, SVM and MLR methods a test set of 19 
compounds is constructed. The regression models 
represent a good harmony between calculated and 
predicted pEC50 values. Like the training set, magnitude 
of squared regression coefficient is higher for BPNN 
(r2= 0.805), MLR (r2= 0.604) as compared to SVM (r2= 
0.575) which indicates BPNN is the best method to be 
used for further assessment than MLR as well as SVM. 
Table 3 presents the observed and calculated pEC50 
values for the training and test sets of ATC derivatives 
using MLR, BPNN and SVM methods.  
 
Table 2 — Comparative analyses of models build by multiple linear regression (MLR), back propagation neural network (BPNN) and 
support vector machine (SVM) techniques (Training set) 
S.No. Model K r2 r2adj rho () PRESS MSE q2 
MLR 
1 MS 9 0.836 0.802 0.765 - 0.150 0.805 
2 LOO 9 0.731 0.675 0.651 13.968 0.258 0.699 
3 NCV (N=10) 9 0.746 0.693 0.661 13.143 0.247 0.722 
BPNN 
1 MS 9 0.845 - 0.743 - 0.142 0.818 
2 LOO 9 0.774 - 0.666 10.937 0.206 0.729 
3 NCV (N=10) 9 0.785 - 0.692 10.517 0.198 0.745 
SVM(ε-radial) 53SV: RBFK 
1 MS 9 0.845 - 0.806 - 0.144 0.807 
2 LOO 9 0.701 - 0.666 - 0.277 0.620 
3 NCV (N=10) 9 0.734 - 0.681 - 0.244 0.649 
SVM(ε-polynomial) 53SV:PK 
1 MS 9 0.840 - 0.803 - 0.147 0.803 
2 LOO 9 0.730 - 0.707 - 0.248 0.653 
3 NCV(N=10) 9 0.750 - 0.716 - 0.230 0.672 
SVM(ε-sigmoid) 53SV:SK 
1 MS 9 0.759 - 0.771 - 0.221 0.678 
2 LOO 9 0.604 - 0.624 - 0.364 0.330 
3 NCV (N=10) 9 0.557 - 0.533 - 0.407 0.236 
SVM(ε-linear) 53SV:LK 
1 MS 9 0.826 - 0.745 - 0.161 0.766 
2 LOO 9 0.730 - 0.710 - 0.279 0.717 
3 NCV (N=10) 9 0.653 - 0.618 - 0.358 0.620 
        (Contd.)




Table 2 — Comparative analyses of models build by multiple linear regression (MLR), back propagation neural network (BPNN) and 
support vector machine (SVM) techniques (Training set) (Contd.) 
S.No. Model K r2 r2adj rho () PRESS MSE q2 
SVM(ν-radial) 29SV:RBFK 
1 MS 9 0.845 - 0.813 - 0.156 0.738 
2 LOO 9 0.738 - 0.727 - 0.241 0.638 
3 NCV (N=10) 9 0.739 - 0.730 - 0.242 0.590 
SVM(ν-plynomial) 29SV:PK 
1 MS 9 0.842 - 0.804 - 0.157 0.737 
2 LOO 9 0.743 - 0.717 - 0.236 0.637 
3 NCV(N=10) 9 0.748 - 0.754 - 0.236 0.584 
SVM(ν-sigmoid) 29SV:SK 
1 MS 9 0.807 - 0.748 - 0.197 0.621 
2 LOO 9 0.675 - 0.655 - 0.307 0.373 
3 NCV (N=10) 9 0.700 - 0.669 - 0.292 0.371 
SVM(ν-linear 29SV:LK 
1 MS 9 0.829 - 0.743 - 0.160 0.812 
2 LOO 9 0.741 - 0.671 - 0.249 0.715 
3 NCV (N=10) 9 0.754 - 0.675 - 0.241 0.736 
MS = Manual Selection, RBFK = Radial Basis Function Kernel, PK = Polynomial Kernel, LK = Linear Kernel. ‘k’ is the no. of 
descriptors, ‘r2’ is the correlation coefficient, ‘q2’ is cross validated ‘r2’ from the (LOO) and N-CV procedures, rho () is the Spearman 
rank correlation coefficient, MSE is the mean squared error and PRESS is the predictive sum of squares. 
 
 
Table 3 — Observed and calculated values of pEC50 (in µM terms) for the training and test sets of ATC derivatives using MLR,  
BPNN and SVM Techniques 
S.No. Comp no. pEC50 
(µM ) 
















1.  1a 6.40 7.41 7.61 7.42 7.43 8.03 7.17 7.36 7.39 7.78 7.29 
2.  2 4.96 5.44 5.26 5.56 5.61 5.71 5.62 5.45 5.45 5.87 5.34 
3.  3 4.96 4.49 4.49 4.88 4.92 4.29 4.87 4.66 4.66 4.83 4.42 
4.  4 4.96 5.64 5.60 5.75 5.76 6.42 5.56 5.87 5.89 6.27 5.45 
5.  5 4.96 4.71 4.62 4.95 4.96 4.96 4.88 5.02 5.04 5.21 4.57 
6.  6a 5.00 6.49 6.70 6.57 6.57 6.81 6.50 6.41 6.41 6.79 6.38 
7.  7a 4.96 7.33 6.39 7.37 7.16 7.26 7.80 7.05 7.23 6.79 7.17 
8.  8a 5.22 6.56 6.22 6.57 6.53 6.19 6.93 6.36 6.35 6.30 6.47 
9.  9a 4.96 7.37 7.10 7.23 7.17 8.10 7.27 7.21 7.22 7.55 7.14 
10.  10a 5.22 6.81 6.86 6.75 6.74 7.27 6.77 6.68 6.67 7.06 6.64 
11.  11a 5.92 6.62 6.76 6.63 6.63 6.97 6.62 6.51 6.50 6.89 6.49 
12.  12 6.42 6.97 6.46 6.92 6.85 6.95 7.30 6.75 6.78 6.71 6.84 
13.  13a 5.46 6.57 6.50 6.58 6.55 6.52 6.74 6.44 6.44 6.57 6.45 
14.  14 7.52 7.47 7.62 7.25 7.15 7.36 7.49 7.20 7.20 7.28 7.30 
15.  15 7.00 7.64 7.53 7.59 7.57 8.30 7.57 7.40 7.37 7.78 7.47 
16.  16 7.00 7.44 7.46 7.40 7.39 7.64 7.44 7.31 7.31 7.49 7.35 
17.  17 7.60 7.74 7.76 7.70 7.69 7.79 7.78 7.64 7.64 7.70 7.74 
18.  19 8.10 7.36 7.44 7.30 7.29 7.77 7.31 7.13 7.11 7.51 7.22 
19.  21 8.22 7.82 7.80 7.71 7.69 7.86 7.85 7.68 7.68 7.74 7.81 
20.  22 7.46 7.31 7.43 7.33 7.32 7.46 7.27 7.22 7.23 7.40 7.22 
21.  23 8.00 7.20 7.40 7.19 7.18 7.51 7.13 7.01 7.00 7.37 7.06 
22.  24 8.10 7.78 7.86 8.06 7.96 8.10 7.92 7.76 7.76 7.61 7.68 
23.  25 8.00 7.76 7.76 8.00 7.97 7.95 7.98 7.61 7.61 7.58 7.71 
24.  28 7.40 6.88 6.95 7.09 7.12 7.12 6.81 7.06 7.10 7.15 6.84 
25.  29 7.15 7.39 7.46 7.16 7.16 7.30 7.39 7.21 7.24 7.37 7.45 
(Contd.)




Table 3 — Observed and calculated values of pEC50 (in µM terms) for the training and test sets of ATC derivatives using MLR,  
BPNN and SVM Techniques (Contd.) 
S.No. Comp no. pEC50 
(µM ) 
















26.  30 8.00 7.42 7.45 7.51 7.50 7.47 7.39 7.42 7.45 7.46 7.37 
27.  31 8.82 8.10 8.09 8.01 8.02 7.95 8.07 7.88 7.87 7.96 8.17 
28.  32 7.30 7.86 7.70 7.79 7.77 7.73 7.86 7.67 7.69 7.69 7.77 
29.  33 8.30 8.44 8.43 9.29 9.40 8.89 8.21 8.66 8.64 8.73 8.70 
30.  34a 7.22 8.38 8.31 8.58 8.63 8.48 8.29 8.37 8.34 8.38 8.52 
31.  35 7.46 7.67 7.69 7.66 7.64 7.56 7.73 7.56 7.58 7.59 7.67 
32.  36 6.70 7.05 7.13 6.88 6.86 7.17 7.00 7.03 7.07 7.18 6.98 
33.  37 6.70 6.70 6.87 6.99 7.01 6.82 6.65 6.92 6.97 6.99 6.68 
34.  38a 6.40 7.22 7.42 6.79 6.77 7.02 7.21 6.96 6.99 7.22 7.29 
35.  39 7.40 7.37 7.40 7.41 7.40 7.18 7.35 7.29 7.33 7.31 7.29 
36.  40 7.70 7.92 8.07 7.67 7.66 7.67 7.86 7.65 7.64 7.81 8.00 
37.  41 7.70 7.69 7.65 7.68 7.64 7.43 7.70 7.53 7.56 7.53 7.62 
38.  42 7.52 7.74 8.09 7.75 7.72 7.64 7.51 7.67 7.65 7.86 7.90 
39.  43 8.10 7.68 7.60 7.90 7.87 7.69 7.66 7.68 7.75 7.51 7.61 
40.  44 8.00 7.68 7.81 7.97 7.96 7.83 7.57 7.75 7.80 7.64 7.62 
41.  45 7.70 7.68 7.60 7.90 7.87 7.69 7.66 7.68 7.75 7.51 7.61 
42.  46 7.70 7.41 7.25 7.74 7.69 7.50 7.33 7.58 7.69 7.29 7.27 
43.  47 8.10 7.87 8.00 8.18 8.20 8.01 7.86 7.89 7.89 7.86 7.95 
44.  48 8.15 7.95 7.85 8.09 8.08 7.87 8.00 7.80 7.83 7.73 7.96 
45.  49 7.00 7.19 7.20 6.99 6.98 7.20 7.19 7.16 7.18 7.26 7.19 
46.  50 7.52 7.40 7.50 7.27 7.26 7.42 7.43 7.38 7.40 7.45 7.44 
47.  51a 5.25 6.73 6.67 6.56 6.56 6.92 6.64 6.83 6.88 6.98 6.69 
48.  52 8.05 7.93 7.82 7.71 7.69 7.72 7.93 7.71 7.72 7.73 7.91 
49.  53 8.10 7.66 7.61 7.44 7.42 7.51 7.70 7.50 7.51 7.55 7.67 
50.  54 6.40 6.74 6.59 6.47 6.44 6.53 6.70 6.71 6.74 6.90 6.81 
51.  55 8.10 8.03 8.23 8.09 8.13 8.11 7.94 7.98 7.96 8.12 8.21 
52.  56a 7.15 7.77 7.94 7.53 7.53 7.58 7.73 7.48 7.48 7.70 7.87 
53.  57 7.70 8.41 8.22 8.25 8.25 8.10 8.41 8.06 8.04 8.17 8.57 
54.  58 8.15 7.88 7.71 7.83 7.81 7.58 7.90 7.74 7.76 7.66 7.85 
55.  60 7.52 7.47 7.77 7.53 7.50 7.55 7.42 7.47 7.52 7.49 7.49 
56.  61 7.40 7.49 7.55 7.43 7.38 7.41 7.43 7.39 7.46 7.36 7.43 
57.  62a 6.00 7.23 7.18 7.22 7.14 7.20 7.15 7.25 7.36 7.13 7.10 
58.  63 7.30 7.74 7.81 7.64 7.62 7.58 7.73 7.52 7.55 7.58 7.75 
59.  64 6.70 7.10 7.14 6.78 6.75 6.92 7.04 6.97 7.01 7.11 7.03 
60.  65a 6.52 7.21 7.45 7.06 7.03 7.13 7.19 7.19 7.22 7.29 7.25 
61.  66a 5.05 6.58 6.58 6.33 6.32 6.63 6.52 6.64 6.69 6.83 6.56 
62.  67 7.30 7.73 7.78 7.51 7.47 7.43 7.72 7.53 7.54 7.58 7.73 
63.  69a 7.05 7.84 8.22 7.73 7.74 7.82 7.72 7.73 7.72 7.97 8.02 
64.  70a 7.22 8.22 8.20 7.87 7.84 7.81 8.21 7.80 7.78 8.01 8.39 
65.  71 7.30 7.72 7.68 7.74 7.70 7.30 7.73 7.61 7.64 7.52 7.70 
66.  72a 6.30 7.88 7.92 7.75 7.75 8.11 7.77 7.81 7.84 8.02 7.91 
67.  73a 6.46 8.34 8.26 8.33 8.35 8.49 8.20 8.21 8.23 8.45 8.55 
68.  74 7.52 7.42 7.29 7.53 7.51 6.90 7.44 7.40 7.43 7.30 7.49 
69.  75 7.70 7.26 7.27 7.50 7.49 6.87 7.14 7.38 7.41 7.28 7.31 
70.  76 5.59 5.60 5.55 5.70 5.63 6.17 5.59 5.93 5.96 6.02 5.38 
71.  77 4.77 4.64 4.96 4.78 4.79 4.84 4.75 5.09 5.12 5.19 4.65 
72.  78 6.16 6.79 6.83 6.70 6.61 7.02 6.86 6.73 6.73 6.81 6.61 
aCompounds in Test set  







Fig. 3 — A graph of comparative analyses between observed and 
calculated pEC50 using MLR, ANN and SVM techniques for 




Fig. 4 — A graph of comparative analyses between observed and 
calculated pEC50 using MLR, ANN and SVM techniques for test 
set of ATC derivatives. 
 
Figs 3 and 4 give a graphical representation of 
relation of observed and predicted pEC50 values for the 
training and test sets respectively using all the three 
chemometric, namely MLR, BPNN and SVM, methods. 
 
Virtual dataset 
A virtual dataset (VDS) of 500 compounds, by 
making fragmental changes on the template ATC 
structure, is created. The antiviral activity of these 
compounds is predicted using the best derived BPNN 
model. A set of 26 virtual compounds was found to have 
predicted anti-viral activity (pEC50) above 8.00µM. 
Table S2 (Supplementary Data) presents the structural 
data of all the virtual compounds exhibiting antiviral 
activity greater than 8.00 µM. Of these 26 compounds 7 
compounds have shown predicted antiviral activity 
greater than 8.5 µM and are given in Table 4. 
Table 4 — Structure of lead compounds (Virtual Data Set, pEC50 











































From the present study on following conclusions 
can be made: The QSAR studies show that structural 
characteristics of ATC derivatives strongly affect 
their antiviral activity. Four analyses namely 
Univariate linear regression (ULR), Multiple linear 
regression (MLR), support vector machine (SVM) 
and Back Propagation Neural Network (BPNN) have 
been performed. The better performance of BPNN 
model over MLR and SVM models is suggestive of 
the fact that there exists a non-linear relationship 
between the independent (descriptors) and dependent 
(antiviral activity) variables. The univariate 
correlation was performed solely with an aim to 
understand potential of descriptors in individual 
capacity in affecting the antiviral activity. In the case 
of univariate linear correlation, ER1 showed highest 
while EO8 and EO9 have lowest linear relationship with 
an antiviral activity. From the results, higher value of 
correlation coefficient (r2) for BPNN and SVM but 
low value for MLR, it is concluded that there is a 
nonlinear relationship between E-state descriptors and 
antiviral activity. In all the regression methods 
(BPNN, SVM and MLR) manual selection method 
performed better than leave-one-out (LOO) and  
N-cross validation method. A test set was used for 
cross validation of derived model. The results of the 
test set are encouraging which proved the robustness 
of models. Six compounds (18, 20, 26, 27, 29 and 68) 
were observed as outliers due to a vast difference in 
the observed and calculated antiviral activity due to 
diverse structural features. 
The most significant conclusions of the present 
study are following: Results suggested that the 
presence of “S” (sulphur) and bridging “O” (oxygen) 
atoms present at position ‘16’ and ‘14’ are beneficial 
for antiviral activity. The model also indicates that 
presence of “N” (nitrogen) atom and double bond 
oxygen atom (of pyrrolidine-2,5-dione ring) at 
positions '9' and '8' respectively in the parent 
compound is favourable for the antiviral activity. 
Substitution at position “R1” is more beneficial for 
antiviral activity than at position “R”. Other 
descriptors such as “RingA”, tri-substituted amine at 
position '17', and carbonyl oxygen group at position 
'19' exhibit a low impact on the antiviral activity. The 
virtual dataset designed on the basis of 
aforementioned observations yielded 26 compounds 
with high biological activity profile which suggest 
that structural attributes of derivatives play a crucial 
role in the field of molecular modeling. 
For the virtual dataset compounds it is observed 
that presence of 3-methylaniline phenyl at position 
‘R1’ along with 4-chloro benzene group at R position 
on parent structure produced highest activity 
enhancing effect (VDS01). Similarly presence of 
bulky groups such as 4-(dicyclopenta-1,3-dien-
1yl)methyl benzene(VDS02), 4-(methylene) 
dibenzene (VDS03), 3-(diphenylamino) benzene 
(VDS04), 2-((2H-pyrrol-3-yl)(3H-pyrrol-4-yl)methyl-
benzene (VDS05), 3-(dicyclopenta-1,3-diene-1yl) 
methylbenzene (VDS06), 2-(diphenylamino) benzene 
(VDS07) groups at position ‘R1’ respectively along 
with 4-chloro benzene group at R position on parent 
structure are conducive and impart activity enhancing 
effect. These 26 compounds can be treated as leads 
for further refinement to derive compounds with 
further higher antiviral activity. 
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